View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 25, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 22,879,950 shares, corresponding to 4.88% (previously 5.01%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instrumen...

 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 21, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,464,124 shares, corresponding to 5.01% (previously 4.94%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instrumen...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Novonesis will host an educational conference call on Energy on Decemb...

Novonesis will host an educational conference call on Energy on December 18 Novonesis will host a spotlight educational session on our Energy activities which is part of Planetary Health Biosolutions. We will share insights about the industry, its development, and Novonesis’ integral part of the industry’s value chain. The session will be hosted as a conference call on December 18 at 15:00 CET. To join the live webcast, please click . To register and receive access details for the conference call, please click . Attachment

ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Jan Erik Gjerland

Storm models approved by NFSA

Release NOK 1.3bn of capital requirements, and its NOK 900m Tier 2 issue.up the proforma solvency ratio to ~185% as of 30 Sept 2024 (from 164%). Could up consensus dividend expectations for both 2024e-25e, positive.

 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 11, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,180,630 shares, corresponding to 4.94% (previously 5.02%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instr...

ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Jan Erik Gjerland
 PRESS RELEASE

Q3 update: Novonesis delivers strong Q3 results and now expects full-y...

Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%. COPENHAGEN, Denmark – November 7, 2024. Novonesis delivers 9% organic sales growth, in the fir...

 PRESS RELEASE

Trading statement 9M 2024

Trading statement 9M 2024 Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5%. Ester Baiget, President & CEO: “We continue to execute strongly across the business. Supportive, broad-based demand coupled with strong innovation and commercial focus drive higher market penetration. Novonesis’ biosolutions are increasingly requested by customers to make their products and processes healthier and more efficient, with less...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management Announcement released on November 4, 2024 at 10:07:51 CET did not include PDF file. Please see the full announcement in the attached PDF file. Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the 2022 legacy Chr. Hansen restricted stock units (RSU) program. Please read the full announcement in PDF.

Delphine Brault ... (+2)
  • Delphine Brault
  • Quentin Borie

KONE : La Chine gâche une nouvelle fois la fête au T3

>Un T3 2024 inférieur aux attentes, à l’exception des commandes - Les commandes ont progressé de 5.5% à changes constants au T3 (css à 0.6% et ODDO BHF à 2%), grâce notamment au segment modernisation (+ 20%) et malgré un recul de plus de 15% des commandes en nouveaux équipements (en volumes) en Chine. La marge brute des commandes est en léger recul par rapport au T3 2023 et en séquentiel, du fait de la Chine. Le CA progresse de 1.1% à changes constants au T3, ave...

Delphine Brault ... (+2)
  • Delphine Brault
  • Quentin Borie

KONE : China spoils the party again in Q3

>Q3 2024 below forecasts, with the exception of order intake - Order intake was up by 5.5% at constant currency (cc) in Q3 (consensus at 0.6% and ODDO BHF at 2%), notably thanks to the modernisation segment (+20%) and despite a decline of more than 15% in orders for new equipment (in volume terms) in China. Gross margin on order intake was down slightly vs Q3 2023 and on a sequential basis, due to China. Revenue was up 1.1% cc in Q3, with activity in China down 2...

ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Anders Idborg
  • Karl Bokvist
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch